BRNS news

Latest 1 stories · newest Aug 6, 2026

BRNS

Barinthus Bio reports Q2 2026 results, completes VTP-1000 MAD enrollment

Barinthus Bio reported Q2 financial results and noted 42 planned subjects were enrolled in the Phase 1 AVALON trial for its celiac disease candidate, with data expected in Q4 2026. Additionally, the company completed enrollment for the MAD portion of the trial, signaling progress towards clinical da…

Earnings|Guidance|Corporate Updates Aug 6, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same BRNS feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/BRNS/newsSTART FREE